(NASDAQ: CRSP) Crispr Therapeutics Ag's forecast annual revenue growth rate of 167.65% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 113.34%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.17%.
Crispr Therapeutics Ag's revenue in 2026 is $38,337,000.On average, 31 Wall Street analysts forecast CRSP's revenue for 2026 to be $12,154,591,717, with the lowest CRSP revenue forecast at $0, and the highest CRSP revenue forecast at $145,523,455,791. On average, 20 Wall Street analysts forecast CRSP's revenue for 2027 to be $27,313,999,780, with the lowest CRSP revenue forecast at $1,541,004,768, and the highest CRSP revenue forecast at $224,241,448,249.
In 2028, CRSP is forecast to generate $79,945,459,459 in revenue, with the lowest revenue forecast at $9,806,393,976 and the highest revenue forecast at $512,334,052,608.